Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models

Japanese Journal of Pharmacology

Volumn 70, Issue 2, 1996, Pages 129-138

  Xue, Yi Xue ^a   Eto, Koji ^a   Akie, Yasuki ^a   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Ischemia; Programmed electrical stimulation; Reperfusion arrhythmia; Sematilide; Ventricular arrhythmia

Indexed keywords

ADRENALIN; DIGITALIS; SEMATILIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DOG; FEMALE; HEART AUTOMATICITY; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; REENTRY ARRHYTHMIA;

EID: 0029987125     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.129     Document Type: Article

References (26)

1. Ruberman W, Weinblant E, Goldberg JD, Frank CW and Shapiro S: Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 279, 750-757 (1977)
2. Singh BN and Vaughan Williams EM: A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacologic actions on cardiac muscle, of MJ 1999 and AH 3474. Er J Pharmacol 39, 675-687 (1970)
3. Nattel S: Antiarrhythmic drug classification: a critical appraisal of their history, present status, and clinical relevance. Drugs 5, 672-701 (1991)
4. Vaughan Williams EM: A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 24, 129-147 (1984)
5. Echt DS, Liebson PR, Mitchell B, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene L, Huther ML, Richardson DW and The CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324, 781-788 (1991)
6. Morganroth J and Goin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 84, 1977-1983 (1991)
7. Herre JM, Sauve MJ, Malone P and Scheinman MM: Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13, 442-449 (1989)
8. Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefeld C and Zipes DP: Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 125, 109-120 (1993)
9. Argentieri TM and Carroll MS: Electrophysiologic mechanism of action of the class III antiarrhythmic agents sematilide and clofilium. J Mol Cell Cardiol 22, Supp III, S.81 (1990)
10. Krafte DS and Volberg WA: Voltage dependence of cardiac rectifier block by methanesulfonamide class III antiarrhythmic agents. J Cardiovasc Pharmacol 23, 37-41 (1994)
11. Sullivan ME, Argentieri TM and Reiser HJ: Electrophysiologic, antiarrhythmic and hemodynamic profile of sematilide HCI in canine cardiac tissues. J Mol Cell Cardiol 22, S.70 (1990)
12. Chi L, Mu D-X, Driscoll EM and Lucchesi BR: Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 16, 312-324 (1990)
13. Hashimoto K: Correlation between the antiarrhythmic effects of drugs and their electrophysiological effects. In Current Topics in Antiarrhythmic Agents, Edited by Toyama J and Hondeghem LM, pp 144-147, Excerpta Medica, Amsterdam, Princeton, Hong Kong, Tokyo and Sydney (1989)
14. Hashimoto K, Satoh H, Shibuya T and Imai S: Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia. J Pharmacol Exp Ther 223, 801-810 (1982)
15. Hashimoto K, Ishii M, Komori S and Mitsuhashi H: Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: A comparative study using other canine arrhythmia model and the new antiarrhythmic drugs, propafenone, tocainide and SUN 1165. Heart Vessels 1, 29-35 (1985)
16. Shibuya T, Hashimoto K and Imai S: Effective plasma concentrations of antiarrhytbmic drugs against sustained halothaneadrenaline arrhythmia in dogs. J Cardiovasc Pharmacol 5, 538-545 (1983)
17. Dancik S, Koziol T, Nisperos E and Woolf E: Determination of sematilide in plasma by high-performance liquid chromatography. J Pharmacol Sci 80, 157-159 (1991)
18. Argentieri TM: Sematilide. Cardiovasc Drug Rev 10, 182-198 (1992)
19. Hashimoto K: Arrhythmias associated with myocardial ischemia and their modulation by antiarrhythmic drugs. Circ Cont 13, 373-383 (1992)
20. Hashimoto K, Haruno A, Matsuzaki T, Hirasawa A, Awaji T and Uemura Y: Effects of a new class III antiarrhythmic drug (E-4031) on canine ventricular arrhythmia models. Asia Pacific J Pharmacol 6, 127-137 (1991)
21. Hashimoto K, Haruno A, Hirasawa A, Awaji T, Xue YX and Wu ZJ: Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. Jpn J Pharmacol 68, 1-9 (1995)
22. Karagueuzia HS and Mandel WJ: Electrophysiologic mechanisms of ischemic ventricular arrhythmias: Experimental-clinical correlation. In Cardiac Arrhythmias. Their Mechanisms, Diagnosis, and Management, Edited by Mandel WJ, pp 452-474, Lippincott, Philadelphia (1987)
23. Akiyama T: Intracellular recording of in situ ventricular cells during ventricular fibrillation. Am J Physiol 240, H465-H471 (1981)
24. Pogwizd SM and Corr PB: Reentrant and nonreentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: Results using three-dimensional mapping. Circ Res 61, 352-371 (1987)
25. Pogwizd SM and Corr PB: Electrophysiologic mechanism underlying arrhythmias due to reperfusion of ischemic myocardium. Circulation 76, 404-426 (1978)
26. Hashimoto K and Hashimoto K: The mechanism of sensitization of the ventricle to epinephrine by halothane. Am Heart J 83, 652-658 (1972)